(2)
Silicon Valley tech firm brings encrypted solution for tracking Canadian developer s 15-minute Covid19 rapid antigen test for point of care, and then at-home testing
Toronto, Ontario (Newsfile Corp. - April 28, 2021) - Afero has entered into a memorandum of understanding (MOU) agreement with Therma Bright Inc. (TSXV: THRM), the Company or Therma Bright ), developer of the AcuVid COVID-19 Rapid Antigen Saliva Test and other progressive diagnostic and medical device technologies. The mutually beneficial partnership looks to bring Afero s innovation, security and tracking technology to Therma Bright s 15-minute COVID-19 rapid antigen screening solution. Upon completion, the proposed agreement will offer AcuVid COVID-19 Rapid Antigen Saliva Tests powered by Afero, with a goal to help communities safely and securely return to work and play using an embedded and encrypted technology for tracking and reporting AcuVID Tests for quality assurance, shipping, logistics, and point-of-ca